The Pipeline Center

Filter Your Results

 

News

 

Retina News

Aflibercept Label Now Includes 12-Week Dosing Interval for AMD The US FDA in August approved an updated label for afl…

Retina News

NOVARTIS PLANS TO SPIN OFF ALCON Novartis plans to spin off its eye care devices division, Alcon, into a separately t…

Topical Drug Delivery for Retinal Disease Management

Topical modes of delivery are being evaluated by a variety of researchers for their potential in retinal disease tre…

David S. Boyer, MD

Less Invasive Treatment for Uveitis

I’ve been interested in intraocular sustained drug delivery systems for years, and I have participated in clin…

Glenn J. Jaffe, MD

A Long-Term Treatment Option for AMD?

Treatment of wet age-related macular degeneration (AMD) with anti-VEGF agents currently requires a regimen of frequent…

An interview with Carl D. Regillo, MD

Retina News

Ablate-and-Replace Gene Therapy Was Successful in Mouse Model of RP An approach to gene therapy in which a gene editi…

Opinion: Paving the Way to Accessible Treatment for All

At a recent meeting of the US Food and Drug Administration’s Cellular, Tissue, and Gene Therapies Advisory Com…

Thomas Ciulla, MD, MBA

Novel Treatment Strategies for Diabetic Eye Disease

There is no doubt that anti -- VEGF-A monotherapy has revolutionized the treatment of diabetic macular edema (DME). …

Pravin U. Dugel, MD

 

This Month's Supplements

 
 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Karen Roman
Editor-in-Chief
484-581-1827
kroman@bmctoday.com

Janet Burk
Publisher
214-394-3551
jburk@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.